Skip to main content
      PsA Predictors
      The multimillion dollar question for inflammatory arthritis prescriptions is: which drug should I use next?
      CAR T cell therapy took the centre stage in 2022 where data pertaining to a successful case series of 5 patients with refractory SLE were published by Prof Schett’s group. Since then, this area of therapeutic has expanded exponentially. Our growing enthusiasm was slightly dampened though when the FDA required all six approved CAR T-cell therapies in oncology to include a black box warning regarding the risk of second primary malignancies in
      Following the landmark case series by the Erlangen group, multiple cellular therapies have entered the race—each with unique targets, constructs, and mechanisms. Yet, a fundamental question remains: How deep is the B-cell depletion? In clinical practice, peripheral blood counts often serve as our surrogate for depletion. But these may only tell part of the story.
      AI continues to move from research labs into rheumatology clinics, promising to reshape how inflammatory diseases are diagnosed and monitored. Ankylosing spondylitis, in particular, poses a diagnostic challenge—its early imaging findings are subtle, and radiographic changes may take years to appear and require specific musculoskeletal radiology expertise. A new deep learning model offers a glimpse into how AI could bridge this diagnostic gap.
      Sjögren's disease has been a difficult space for new FDA approvals. At ACR 2025, two late breaking abstracts have triggered hope for patients suffering from Sjögren's disease.
      ×